Atlas Trials

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Clinical trial NCT05214339 · UNKNOWN

Trial details

NCT number
NCT05214339
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma by BCLC Stage
Start date
2022-03-16
Primary completion
2023-01-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.